Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2025-03-24 Audit Report / Informat…
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'NKMAX' (주식회사 엔케이맥스) for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. While it contains financial data, it is the official audit report issued by an accounting firm (대주회계법인), which falls under the 'Audit Report / Information' category. FY 2024
2025-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides the auditor's opinion (which is 'Disclaimer of Opinion' or '의견거절'), financial highlights, and details regarding the company's financial status. While it contains audit-related information, it is a standard regulatory disclosure form used in the Korean market to announce the receipt and filing of the audit report, rather than the full audit report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2024
2025-03-21 Korean
주권매매거래정지기간변경 (상장폐지 사유 발생)
Delisting Announcement Classification · 100% confidence The document is a regulatory announcement regarding the suspension of stock trading for NKMAX Co., Ltd. due to delisting-related issues (audit opinion concerns and listing eligibility). It is a formal notice issued to the exchange and shareholders regarding trading status, which falls under general regulatory announcements.
2025-03-21 Korean
기타시장안내 (상장폐지 관련)
Delisting Announcement Classification · 100% confidence The document is an official notice from the KOSDAQ market regarding the potential delisting of NKMAX due to an 'adverse opinion' (disclaimer of opinion) from auditors. It outlines the regulatory grounds for delisting, the timeline for filing an objection, and the review process. This is a formal regulatory announcement concerning the status of the company's listing, which fits the definition of a delisting-related announcement.
2025-03-21 Korean
[기재정정]기타경영사항(자율공시) (관계인집회 기일 결정)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from NKMAX regarding a change in the date for a creditors' meeting (rehabilitation proceedings) in the Seoul Rehabilitation Court. It is a 'Correction Report' (정정신고) updating a previous disclosure. Since it pertains to legal proceedings and court-mandated rehabilitation schedules, it falls under the category of legal/regulatory updates. As it does not fit into specific categories like M&A or financial reports, it is classified as a Regulatory Filing (RNS).
2025-03-13 Korean
내부결산시점관리종목지정ㆍ형식적상장폐지ㆍ상장적격성실질심사사유발생
Delisting Announcement Classification · 100% confidence The document is a regulatory filing from a Korean company (NKMax) announcing the occurrence of grounds for administrative designation, potential delisting, and substantive review of listing eligibility due to capital impairment and financial losses identified during internal closing. This is a mandatory disclosure of material financial events to the stock exchange, which falls under the 'Regulatory Filings' category as it does not fit into standard periodic reports or specific corporate actions like dividends or M&A.
2025-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.